Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Johnson & Johnson
JNJ
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $611.4B
$262.26
▲ +3.26%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$154.21 - $262.34
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 63.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Diversified portfolio across pharmaceuticals and medical devices reduces revenue concentration risk
- Extensive R&D capabilities and pipeline of innovative treatments in high-demand therapeutic areas
- Strong brand recognition, global distribution networks, and established healthcare relationships
- Regulatory expertise and proven ability to navigate complex drug approval processes
Bear Case
2 risks
- Low volatility (beta 0.3).
- Premium valuation to Large Cap Pharma peers
Growth
Moderate growth ahead
Aging global population increasing demand for chronic disease treatments and medical devices
Value
Premium valuation to Large Cap Pharma peers
Momentum
Stable
+4.5% over 3m
Quality
Excellent
Excellent business quality
Dividend
Solid
2.06% yield
Smart-money signal
Who's buying JNJ right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 21, 2026
APR 14, 2026
Reported EPS of $2.70 vs $2.68 consensus (+0.8% surprise). Revenue of $24.1B vs $23.6B expected (+1.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+0.8%
Next: Apr 21, 2026
Revenue trend · last 8Q
—
—
+5%
+2%
+6%
+7%
+9%
+10%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$22.4B
$22.5B
$22.5B
$21.9B
$23.7B
$24.0B
$24.6B
$24.1B
Margins · last 8Q
Gross
—
Operating
—
Profit
21.8%
Wall Street consensus
16 analysts · 56% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
56%
Hold
44%
Sell
0%
Median Price Target
$265.00
▲ +1.0% vs $262.26
Latest: Guggenheim · Jun 26, 2026
6 analysts covering